Archives: Research
Research & Insights Content Type
-
Fact Checking the NYT Fact Check on the Trump Proposal
-
A $475,000 price tag for a new cancer drug: crazy or meh?
-
US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light
-
The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
-
Remdesivir Less Expensive for “Government Programs”? Not So Fast.
-
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
-
Blueprints for Indication-Specific Pricing
-
Pharmaceutical Products and Their Value
-
Understanding the Rewards of Successful Drug Development: Thinking Inside the Box
-
Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection